Patents Examined by Rodney P Swartz
  • Enrichment methods for the detection of pathogens and other microbes
    Patent number: 10724068
    Abstract: Methods for enrichment and detection of pathogens or other microbes in a food, water, wastewater, industrial, pharmaceutical, botanical, environmental samples and other types of samples are provided. Certain aspects provide diluting the sample with liquid enrichment medium at a ratio of sample to diluent between about 1:0.1 to about 1:9 (wt./vol.), or lesser dilution. In particular aspects, a sample is obtained and diluted at a first location, and incubated at an optimal temperature and either tested locally, or sent in a shipping incubator to a second location that may be a remote test location for testing with an assay suitable to detect the pathogen or other microbe. In particular embodiments, no dilution at the first location is required, and optional minimal additions to adjust intrinsic deficiencies may be made, but the sample is nonetheless incubated during transit to the test location.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: July 28, 2020
    Assignee: Institute for Environmental Health, Inc.
    Inventor: Mansour Samadpour
  • Assays for antimicrobial activity and applications thereof
    Patent number: 10718766
    Abstract: The disclosure provides methods, compositions, and kits for enhanced detection of microbes in samples and monitoring of antimicrobial activity in a subject.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: July 21, 2020
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Mark J. Cartwright, Nazita Gamini, Donald E. Ingber, Martin Rottman, Michael Super, Julie A. Tomolonis, Karen A. Sinclair
  • Compositions and methods of enhancing immune responses to enteric pathogens
    Patent number: 10716840
    Abstract: Vaccine vectors capable of eliciting an immune response to enteric bacteria and methods of using the same are provided. The vaccine vectors include a polynucleotide encoding a PAL polypeptide. The PAL polypeptide may be expressed on the surface of the vaccine vector. The vaccine vector may also include a second polypeptide encoding an immunostimulatory polypeptide such as a CD154 polypeptide or an HMGB1 polypeptide.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: July 21, 2020
    Assignees: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Lisa Bielke, Sherryll Layton, Billy Hargis, Neil R. Pumford, Olivia B. Faulkner, Luc Berghman, Daad Abi-Ghanem
  • Compositions and vaccines comprising vesicles and methods of using the same
    Patent number: 10711043
    Abstract: The disclosure relates to compositions, pharmaceutical compositions, vaccines, and methods of making and using the same. The compositions of the disclosure are useful to stimulate an antigen-specific immune response and, in some embodiments, a protective immune response in an animal after challenge to pathogens. The compositions of the disclosure are also useful for treatment and prevention of disease in a subject such as cancer.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: July 14, 2020
    Assignees: University of Maryland, College Park, University of Maryland, Baltimore
    Inventors: Philip R. DeShong, Lenea Stocker, Daniel C. Stein, Stefanie N. Vogel, Katharina Richard
  • Composition for inhibiting survival or growth of tubercle bacillus by adjusting polarization of macrophage, and method using same
    Patent number: 10709765
    Abstract: The present invention provides a composition for inhibiting the survival or growth of a tubercle bacillus, containing a material which induces the polarization of a macrophage into an M1 macrophage, and a method for inhibiting the survival or growth of the tubercle bacillus by using the composition.
    Type: Grant
    Filed: July 4, 2017
    Date of Patent: July 14, 2020
    Assignee: THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC)
    Inventor: Chang-Hwa Song
  • Methods of mitigating the negative effects of endurance exercise
    Patent number: 10702563
    Abstract: Methods for inhibiting the negative metabolic and/or inflammatory impact of endurance exercise by administration of nucleotides is disclosed.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: July 7, 2020
    Assignee: NU Science Laboratories, Inc.
    Inventors: William J. Kraemer, Mark G. Connell
  • Therapeutic treatment of skin disease with recombinant commensal skin microorganisms
    Patent number: 10702558
    Abstract: The invention relates to methods for treating or preventing abnormal skin conditions in a human in need thereof, comprising administering a cell culture composition comprising a living culture of bacteria comprising at least one engineered strain that produces a recombinant polypeptide for therapeutic treatment of the abnormal skin condition. The invention also relates to pharmaceutical compositions containing, as the active principle, engineered microorganisms expressing non-vaccinogenic pharmacologically active recombinant therapeutic polypeptides in order to treat or prevent abnormal skin conditions.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: July 7, 2020
    Assignee: Azitra Inc
    Inventors: Azim Momin Munivar, Travis Michael Whitfill
  • Antigens and epitopes derived from
    Patent number: 10703784
    Abstract: The present invention relates to M. tuberculosis proteins and peptides, and subsequences, portions or modifications thereof and methods and compounds comprising the same for eliciting, stimulating, inducing, promoting, increasing, or enhancing an anti-M. tuberculosis immune response in a subject.
    Type: Grant
    Filed: October 1, 2012
    Date of Patent: July 7, 2020
    Assignee: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Alessandro Sette, Cecilia Arlehamm, Bjoern Peters, Howard Grey, John Sidney
  • Skin microbiome colonizer formulations and methods for use
    Patent number: 10695386
    Abstract: A system for treating and maintaining the health of the skin of a user. The system may include a topical formulation and an oral formulation. The topical formation may include various probiotic organisms selected for enhancing and treating the skin of a user. The oral formulation may include various probiotic organisms for enhancing and treating the skin of the user. The topical formulation and the oral formulation may be used cooperatively and simultaneously to produce a beneficial, synergistic effect.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: June 30, 2020
    Inventor: Shayne K. Morris
  • Assays and methods for detecting mycobacterial infections
    Patent number: 10677797
    Abstract: Provided herein is an assay for detecting a rough-type mycobacterium and a smooth-type mycobacterium in a sample, wherein the mycobacterium is Mycobacterium tuberculosis or Mycobacterium bovis. The assay comprises a first molecule that selectively binds to the rough-type mycobacterium or binds to a molecule preferentially secreted by the rough-type mycobacterium and a second molecule that selectively binds to the smooth-type mycobacterium or binds to a molecule preferentially secreted by the smooth-type mycobacterium. The first molecule and the second molecule are independently detectable. Also provided herein are corresponding methods for detecting a rough-type mycobacterium and a smooth-type mycobacterium in a sample and assays and methods for detecting tuberculosis infection in a sample.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: June 9, 2020
    Assignee: S&R PHARMACEUTICALS, LLC
    Inventor: Tsungda Hsu
  • Flagellin compositions and uses
    Patent number: 10669316
    Abstract: The present invention relates to compositions comprising improved flagellin derived constructs and methods of using the same in the treatment of various diseases.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: June 2, 2020
    Assignee: Genome Protection, Inc.
    Inventor: Vadim Mett
  • Treatment of immune disease by mucosal delivery of antigens using genetically modified
    Patent number: 10668136
    Abstract: The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery by micro-organism, in particular Lactococcus lactis, of secreted immunodominant antigens.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: June 2, 2020
    Assignee: INTREXON ACTOBIOTICS NV
    Inventors: Pieter Rottiers, Veerle Snoeck
  • Immunogenic compositions for use in pneumococcal vaccines
    Patent number: 10653764
    Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention thereforerelates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: May 19, 2020
    Assignee: Pfizer Inc.
    Inventors: David Cooper, Kathrin Ute Jansen, Michael William Pride
  • Influenza mucosal vaccine composition and preparation and application thereof
    Patent number: 10655137
    Abstract: Provided is an influenza mucosal vaccine composition and preparation and application thereof. This composition contains an antigen fusion protein which includes an influenza virus antigen and a Type IIb heat-labile enterotoxin A subunit from Escherichia coli. Immunization with this antigen fusion protein induces cellular and humoral immune responses, including systemic and mucosal immune responses, against a specific influenza virus in a subject, and therefore protects the subject from viral infection.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: May 19, 2020
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Suh-Chin Wu, Shi-Wei Lin, Neos Tang, Ting-Hsung Chen
  • Methods and compositions for reducing vancomycin-resistant infection or colonization
    Patent number: 10646520
    Abstract: The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Clostridium scindens and/or the bacteria Blautia producta contribute substantially to resistance against vancomycin-resistant Enterococci infection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of Clostridium scindens.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: May 12, 2020
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Eric Pamer, Peter McKenney, Silvia Caballero
  • Method for preventing or treating infection
    Patent number: 10639361
    Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: May 5, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventor: Martine Marchand
  • Diagnostic reagents for improved in vivo or in vitro cell-mediated immunological diagnosis of tuberculosis
    Patent number: 10641770
    Abstract: The present invention discloses in vitro and in vivo diagnostic methods with enhanced specificity and sensitivity for the detection of tuberculosis. The diagnostic reagents of the present invention can replace former mixtures/cocktails/pools of antigens comprising ESAT-6 but including ESAT6 improves the diagnosis even further.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: May 5, 2020
    Assignee: Statens Serum Institut
    Inventors: Claus Aagaard, Søren Tetens Hoff, Ida Rosenkrands, Else Marie Agger, Peter Lawætz Andersen
  • Use of a hyperimmune egg product to prevent and treat dysbiosis
    Patent number: 10632158
    Abstract: Methods for treating and preventing dysbiosis in a subject suffering from or susceptible to gastrointestinal disorders are described. The methods comprises administering a hyperimmunized egg product to the subject, wherein the egg product is obtained from a hyperimmunized avian, optionally in combination with an additional compound such as a probiotic and/or nutrient source.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: April 28, 2020
    Assignee: IGY Nutrition
    Inventor: Susan J. Hewlings
  • Composition for preventing alopecia or stimulating hair growth containing extracellular polysaccharide produced from ceriporia lacerata as active ingredient
    Patent number: 10617730
    Abstract: The present invention relates to extracellular polysaccharide produced from Ceriporia lacerata, a mycelium culture medium of Ceriporia lacerata containing the extracellular polysaccharide, and a composition for preventing alopecia or stimulating hair growth containing dry powder or an extract of the mycelium culture medium as an active ingredient. The composition according to the present invention inhibits expression of TGF-? and is thus superb in preventing alopecia or stimulating hair growth and a composition containing said composition can be effectively used as a pharmaceutical composition, quasi-drug, healthy functional food and cosmetic composition for preventing alopecia or stimulating hair growth.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: April 14, 2020
    Assignee: FUGENBIO CO., LTD.
    Inventor: Yoon Soo Kim
  • Extracts of edible fungi enriched in vitamin D and compostions thereof and their use in the treatment of immune-related disorders
    Patent number: 10617697
    Abstract: A vitamin D2-enriched biomass of an edible fungus, extracts and compositions thereof are provided, for use in delaying onset of, treating, ameliorating or protecting from an immune-related or inflammatory related disease, disorder or condition, wherein the level of vitamin D2 in said biomass is at least 80 IU/gr.
    Type: Grant
    Filed: January 17, 2016
    Date of Patent: April 14, 2020
    Assignees: GAVISH-GALILEE BIO APPLICATIONS, LTD., HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD
    Inventors: Dan Levanon, Yaron Ilan, Ofer Danai